Deals
-
Lilly expands its cancer drug work with bet on dual-acting antibodies
An alliance with Merus, a Dutch biotech, continues Lilly's push to revitalize its oncology research under the leadership of former Loxo Oncology executives.
By Ben Fidler • Jan. 19, 2021 -
Dana-Farber launches venture fund targeting incurable cancers
Binney Street Capital plans to invest in eight to 10 companies over the next three years. Developing new drugs will be a core focus, though investments could also go toward health services, digital health or diagnostics.
By Jacob Bell • Jan. 15, 2021 -
5 trends in biotech dealmaking to watch in 2021
Brain drugs, private equity players and blank-check companies are just some of the things deal experts say they'll be keeping an eye on this year.
By Jacob Bell • Jan. 13, 2021 -
Celgene's cell therapy spinout nets $292M from blank-check merger
With additional financing, Celularity will have $372 million to back development of off-the-shelf treatments for cancer and autoimmune diseases.
By Jonathan Gardner • Jan. 08, 2021 -
Leading $105M biotech funding, Bayer deepens cell therapy investment
A Series B investment in Senti Biosciences will support the startup's research on off-the-shelf candidates, as Bayer places another bet on cell therapy.
By Jonathan Gardner • Jan. 06, 2021 -
Biogen pushes further into eye gene therapy with new deal
Partnering with German biotech ViGeneron bolsters Biogen's pipeline of drugs for eye diseases, which includes assets acquired through its buyout of Nightstar Therapeutics.
By Kristin Jensen • Jan. 06, 2021 -
Dewpoint forges another big pharma partnership — and a potential rivalry
The biotech, which works in the emerging research field of biomolecular condensates, is teaming up with Pfizer to find new treatments for a rare type of muscular dystrophy.
By Jacob Bell • Jan. 06, 2021 -
Roche adds to RNA drug deal streak with Ribometrix partnership
The companies' pact is the latest addition to a growing list of deals involving startups developing chemical drugs to target RNA molecules.
By Ben Fidler • Jan. 06, 2021 -
Merck signs $356M deal to supply US with experimental coronavirus drug
The drugmaker spent $425 million a month ago to acquire the biotech developer of the treatment, which tamps down on the body's inflammatory response to viral infections.
By Jonathan Gardner • Dec. 23, 2020 -
Vertex teams up with Skyhawk, leaning on another biotech in bid to diversify
Following a string of deals in edgy, unproven fields of scientific research, Vertex's latest deal involves chemical-based drugs that target RNA — an approach that's already attracted several large pharmas.
By Ben Fidler • Dec. 22, 2020 -
Changing identity, Agios to sell cancer drug business to Servier
Servier will pay Agios $1.8 billion upfront to acquire the biotech's approved leukemia treatment Tibsovo as well as the rest of its pipeline in cancer and early-stage research work.
By Ned Pagliarulo • Dec. 21, 2020 -
Novartis acquires a small biotech and its trio of brain drugs
More active in neuroscience than most pharmaceutical firms, Novartis would gain three experimental drugs for depression, schizophrenia and movement disorders through the deal.
By Jacob Bell • Dec. 17, 2020 -
Column
Pharmacquired: What a surprise deal does for AstraZeneca and Alexion
The $39 billion tie-up would hand AstraZeneca five marketed rare disease drugs, including the pricey medicines Soliris and Ultomiris.
By Jacob Bell • Dec. 16, 2020 -
Lilly pays $880M for Prevail, pushing further into genetic medicine
The acquisition marks a significant bet by Lilly on gene therapy's potential to address tough-to-treat neurological disorders like Parkinson's disease.
By Jonathan Gardner • Dec. 15, 2020 -
Allogene, broadening its reach, helps start a biotech in China
The cell therapy developer is the second company in two days to form a joint venture with Overland Pharmaceuticals, which aims to bring new drugs to Asia.
By Ben Fidler • Dec. 15, 2020 -
AstraZeneca to buy Alexion for $39B
The deal launches AstraZeneca, a company that has been growing mostly because of newer drugs for cancer and diabetes, into the market for rare disease treatments.
By Jacob Bell • UPDATED: Dec. 12, 2020 at 11:32 a.m. -
Lilly's coronavirus drug partner nails down one of biotech's largest IPOs
AbCellera Biologics, a developer of antibody drugs, has raised $483 million through one of the biggest initial public offerings for a biotech in recent years.
By Jacob Bell • Dec. 11, 2020 -
Bayer strikes a deal with Atara, wading deeper into cell therapy
A pact for two Atara programs continues the German pharma's efforts to use dealmaking to build a gene and cell therapy division.
By Ben Fidler • Dec. 07, 2020 -
Biogen stocks up on Sage's brain drugs in $3B deal
Biogen and Sage each face challenges. While executives from both companies said the deal could provide a boost, investors don't appear to be sold just yet.
By Jacob Bell • UPDATED: Nov. 30, 2020 at 11:13 a.m. -
Deep Dive
How Gilead finally spent its money
This year, the biotech spent about $27 billion trying to become a leader in cancer research. Executives who spoke to BioPharma Dive said there's still work to be done.
By Jacob Bell • Nov. 24, 2020 -
Amgen cuts Cytokinetics loose after heart drug disappointment
The smaller biotech vowed to push forward, although the pill's inability to prevent heart failure death may complicate its plans to win approval.
By Jonathan Gardner • Nov. 23, 2020 -
Pfizer strikes a deal with newly formed China biotech
The deal, which has Pfizer paying as much as $70 million, is the latest in a series of moves by big pharma companies to forge a stronger position in the world's second-largest drug market.
By Kristin Jensen • Nov. 19, 2020 -
Japanese drugmaker takes full control of a Roivant biotech
With competition looming over one of its top drugs, Sumitomo Dainippon Pharma has been looking for new portfolio additions. It thinks it found one in Urovant Sciences.
By Jacob Bell • Nov. 13, 2020 -
Lilly backs a biotech's spinout and places a small bet on protein degradation
An alliance with BeyondSpring spinout Seed Therapeutics makes Eli Lilly the latest pharma company to dive into the fast-emerging drug research field.
By Ben Fidler • Nov. 13, 2020 -
UCB strikes 2 gene therapy deals to build its pipeline
With patent expirations nearing for a top-selling drug, the Belgian pharma will buy one company and partner with another to add several early-stage projects in neurological diseases.
By Jonathan Gardner • Nov. 12, 2020